3M Pharmaceuticals, Building 270-3A-01, 3M Center, St. Paul, Minnesota, USA.
- Page(s) : 20-1
- Published in: 1999
As part of the “Recurring Genital Warts” seminar at 6th Congress of European Academy of Dermatology and Venereology, audience members had the opportunity to question the speakers further about their clinical research. Issues raised focused mainly on the clinical efficacy, side effects and recurrence of imiquimod as an immune modifier, and about its potential future application. The questions and answers from this session are presented here.